BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 11665975)

  • 1. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A; Barr SG; Magder LS; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A surge in anti-dsDNA titer predicts a severe lupus flare within six months.
    Pan N; Amigues I; Lyman S; Duculan R; Aziz F; Crow MK; Kirou KA
    Lupus; 2014 Mar; 23(3):293-8. PubMed ID: 24316605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus.
    van den Berg L; Nossent H; Rekvig O
    Clin Rheumatol; 2006 May; 25(3):347-52. PubMed ID: 16328091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
    Ng KP; Manson JJ; Rahman A; Isenberg DA
    Arthritis Rheum; 2006 Dec; 55(6):900-4. PubMed ID: 17139667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
    Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus.
    Mok CC; Ho LY; Leung HW; Wong LG
    Transl Res; 2010 Dec; 156(6):320-5. PubMed ID: 21078493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
    Thanou A; Chakravarty E; James JA; Merrill JT
    Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM; Marx AS; Barry NN
    J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS; Farewell V; Isenberg DA; Rahman A; Teh LS; Griffiths B; Bruce IN; Ahmad Y; Prabu A; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Gordon C
    Arthritis Rheum; 2007 Dec; 56(12):4113-9. PubMed ID: 18050213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus.
    Brunner HI; Mina R; Pilkington C; Beresford MW; Reiff A; Levy DM; Tucker LB; Eberhard BA; Ravelli A; Schanberg LE; Saad-Magalhaes C; Higgins GC; Onel K; Singer NG; von Scheven E; Itert L; Klein-Gitelman MS; Punaro M; Ying J; Giannini EH
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1213-23. PubMed ID: 21618452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S; Karimifar M; Bonakdar ZS; Salesi M
    Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review.
    Floris A; Piga M; Cauli A; Mathieu A
    Autoimmun Rev; 2016 Jul; 15(7):656-63. PubMed ID: 26921641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus.
    Sjoholm AG; Martensson U; Sturfelt G
    J Rheumatol; 1997 May; 24(5):871-8. PubMed ID: 9150075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies.
    Narayanan K; Marwaha V; Shanmuganandan K; Shankar S
    Med J Armed Forces India; 2010 Apr; 66(2):102-7. PubMed ID: 27365721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.